Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
MSDA 2017 REGISTER AND SUBMIT YOUR ABSTRACT ONLINE NOW!
Online registration and abstract submission is now open for the 12th Metabolic Syndrome, Type 2 Diabetes and Atherosclerosis Congress (MSDA 2017), St. Petersburg, Russia, 8-10 June, 2017.
 
Register here for attendance to all scientific sessions and exhibit area, program and abstract
For information on group registration please refer to the MSDA Congress website :
REGISTRATION
 
Submit your abstract now! Abstracts should be prepared in English language and submitted to the MSDA Scientific Committee;
full details are provided here:
ABSTRACT SUBMISSION
Register Now - Don’t miss out!
Be a part of this premier event focused at the cross roads of cardiology,
diabetology and lipidology!
R3i editorial
28 February 2017

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
A global call to action on residual cardiovascular riskRead more...

The developed world has seen substantial improvement in the management of cardiovascular disease (CVD), particularly in the acute setting. Indeed, in Western and Central Europe, these gains in cardiovascular health have been sufficient to counteract demographic forces.
The situation in economically emerging regions is, however, less promising. Increasingly, the vast majority of deaths due to CVD occur here, usually at younger ages than in developed countries, with a correspondingly greater impact on the burden of CVD, both in terms of the individual and societal cost...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
28 February 2017

STRONG HEART study: relationship between atherogenic dyslipidaemia and risk of cardiovascular disease depends on diabetes status. Read more...

Consistent with this month’s theme, this report from the Strong Heart Study provides evidence that the combination of elevated fasting triglycerides and low HDL-C, atherogenic dyslipidaemia, is associated with increased cardiovascular risk in American Indians, especially in those with diabetes. Thus, the study adds evidence...
focus on...
28 February 2017

REMAIN study highlights residual dyslipidaemia in acute coronary syndrome Indian patientsRead more...

Much of the evidence that atherogenic dyslipidaemia, the combination of elevated triglycerides and low HDL-C levels, is associated with increased cardiovascular risk is available from studies conducted in Europe and North America, predominantly in white North Caucasian individuals.1-5 However, as shown by the INTERHEART study...
recent publication

Abdominal adiposity and risk for type 2 diabetes and coronary heart disease Read more...

A report in JAMA supports a causal association between abdominal...
recent publication

Call for action for dyslipidaemia in Middle EastRead more...

This call for action paper from a panel of experts...
recent publication

Impairment of HDL function in post-infarct patientsRead more...

This report shows that the functionality of high-density lipoproteins (HDL)...
recent publication

Increased burden of coronary artery disease with elevated BMIRead more...

Data from the Partners Healthcare CT Registry in consecutive patients...
recent publication

Residual cardiovascular risk in a real-world settingRead more...

One in eight very high risk patients remain at high...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.